Flunarizine for Treatment Resistant Absence Epilepsy
Status:
Terminated
Trial end date:
2023-05-26
Target enrollment:
Participant gender:
Summary
This is an open-label, single-centre study to evaluate the clinical efficacy, safety and
tolerability of Flunarizine administered as adjunctive treatment in participants diagnosed
with treatment resistant absence epilepsy. The study goal is to see how efficient and safe
flunarizine is at decreasing the frequency of absence seizures in children with
treatment-resistant refractory epilepsy at doses of 5mg and 10mg once daily.